|Table of Contents|

Comparison of clinical efficacy and dosimetry parameters of intracavitary/interstitial brachytherapy and three-dimensional image-based after-loading intracavitary brachytherapy in locally advanced cervical cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 01
Page:
115-120
Research Field:
Publishing date:

Info

Title:
Comparison of clinical efficacy and dosimetry parameters of intracavitary/interstitial brachytherapy and three-dimensional image-based after-loading intracavitary brachytherapy in locally advanced cervical cancer
Author(s):
ZOU Yulin; ZHU Sijin; TAN Simeng
Department of Radiotherapy,Yunnan Cancer Hospital,the Third Affiliated Hospital of Kunming Medical University,Yunnan Kunming 650118，China.
Keywords:
locally advanced cervical cancer; intracavitary/interstitial brachytherapy; after-loading intracavitary brachytherapy; dosimetry; short-term efficacy
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2024.01.020
Abstract:
Objective:To evaluate the difference of therapeutic effect and dosimetry between intracavitary/interstitial brachytherapy（IC-ISBT） and three-dimensional(3D) image-based after-loading intracavitary brachytherapy(ICBT) in the treatment of locally advanced cervical cancer(LACC).Methods:The data of 61 patients with cervical cancer who received radical radiotherapy from January 2019 to December 2021 in our hospital were retrospectively analyzed.They were divided into IC-ISBT group and ICBT group according to different treatment methods.The short-term efficacy,the incidence of adverse events,and dosimetric differences between these two groups were compared.Results:The HR-CTV D90% in the IC-ISBT group was higher than that in the ICBT group,and the difference was statistically significant(P=0.026).The rectal D2 cm3,D1 cm3 and bladder D2 cm3 and D1 cm3 were significantly lower in the IC-ISBT group than those in the ICBT group,and the differences showed statistically significant(P＜0.05).The complete response(CR) rate in the IC-ISBT group was significantly higher than that in the ICBT group,and the difference was statistically significant(P＜0.05).The incidence of radiation enteritis in IC-ISBT group was significantly lower than that in the ICBT group,which was statistically significant(P＜0.05).Conclusion:IC-ISBT can significantly increase the target dose while reducing the radiation dose of rectum and bladder.In addition,IC-ISBT can further improve the local control rate of tumors,and reduce the incidence of toxic side reactions.

References:

［1］ARBYN M,WEIDERPASS E,BRUNI L,et al.Estimates of incidence and mortality of cervical cancer in 2018:A worldwide analysis［J］.Lancet Glob Health，2020，8(2):191-203.
［2］HUANG H,FENG YL,WAN T,et al.Effectiveness of sequential chemoradiation vs concurrent chemoradiation or radiation alone in adjuvant treatment after hysterectomy for cervical cancer:The STARS phase 3 randomized clinical trial［J］.JAMA Oncology,2021,7(3):361-369.
［3］JOHN NO,SATHYAMURTHY A,PRASOONA S,et al.Patterns of care and clinical outcomes in stage Ⅳa cervical cancer:14-year experience from a tertiary care centre in South India［J］.Journal of Radiotherapy in Practice,2023,22:e9.
［4］CHANG H,WANG M,LIU Y,et al.Parametrial involvement and decreased survival of women with FIGO stage Ⅲc1 cervical cancer［J］.Journal of Gynecologic Oncology,2023,34(4):e46.
［5］GUANI B,MAHIOU K,CRESTANI A,et al.Clinical impact of low-volume lymph node metastases in early-stage cervical cancer:A comprehensive Meta-analysis［J］.Gynecologic Oncology,2022,164(2):446-454.
［6］CARVALHO HA,MAURO GP.History of radiotherapy in the treatment of uterine cervix cancer:An overview［J］.Revista da Associaǎo Médica Brasileira,2023,69:e2023S126.
［7］LIU R,WANG X,TIAN JH,et al.High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer［J］.Cochrane Database Syst Rev,2014,2014(10):CD007563.
［8］ROGOWSKI P,ROTTLER M,WALTER F,et al.Clinical outcome of combined intracavitary/interstitial brachytherapy using a hybrid applicator in locally advanced cervical cancer［J］.Gynecologic Oncology,2022,166(3):576-581.
［9］HOLM J,GERKE O,VILSTRUP MH,et al.Improved stratification of stage-specific survival for cervical uterine cancer by integrating FDG-PET/CT and MRI for lymph node staging in 2018 FIGO classification［J］.Gynecol Oncol,2022，167(2):152-158.
［10］WRIGHT JD,MATSUO K,HUANG Y,et al.Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics cervical cancer staging guidelines［J］.Obstet Gynecol,2019,134(1):49-57.
［11］P TTER R,TANDERUP K,KIRISITS C,et al.The EMBRACE Ⅱ study:The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies［J］.Clinical and Translational Radiation Oncology,2018,9:48-60.
［12］ EISENHAUER EA,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:Revised RECIST guideline(version 1.1)［J］.European Journal of Cancer,2009,45(2):228-247.
［13］KOH WJ,GREER BE,ABU-RUSTUM NR,et al.Cervical cancer,version 2.2015［J］.J Natl Compr Canc Netw,2015,13(4):395-404.
［14］TANDERUP K,EIFEL PJ,YASHAR CM,et al.Curative radiation therapy for locally advanced cervical cancer:Brachytherapy is NOT optional［J］.International Journal of Radiation Oncology,Biology,Physics,2014,88(3):537-539.
［15］WALTER F,MAIH FER C,SCH TTRUMPF L，et al.Combined intracavitary and interstitial brachytherapy of cervical cancer using the novel hybrid applicator Venezia clinical feasibility and initial results［J］.Brachytherapy，2018，17（5）:775-781.
［16］CHRISTIAN K，STEFAN L，JOHANNES D，et al.The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer:Design，application，treatment planning，and dosimetric results［J］.Int J Radiat Oncol Biol Phys，2006，65(2):624-630．
［17］FOKDAL L,TANDERUP K,HOKLAND SB,et al.Clinical feasibility of combined intracavitary/interstitial brachytherapy in locally advanced cervical cancer employing MRI with a tandem/ring applicator in situ and virtual preplanning of the interstitial component［J］.Radiotherapy and Oncology,2013,107(1):63-68.
［18］SHARMA DN,SUBRAMANI V,RATH GK,et al.Interstitial brachytherapy guided intensity modulated radiation therapy in cervical carcinoma:A dosimetric study［J］.International Journal of Radiation Oncology,Biology,Physics,2007,69(3):S731-S732.
［19］NOMDEN CN,DE LEEUW AA,MOERLAND MA,et al.Clinical use of the Utrecht applicator for combined intracavitary/interstitial brachytherapy treatment in locally advanced cervical cancer［J］.Int J Radiat Oncol Biol Phys,2012,82(4):1424-1430.
［20］安菊生，黄曼妮，徐英杰,等.宫颈癌常规放疗联合腔内三维放疗的初步研究［J］,中华放射肿瘤学杂志,2014,23(5):373-376. AN JS,HUANG MN,XU YJ,et al.Preliminary study on relationship between DVH parmneters and late side efects of rectmn in external-beam radiotherapy combined with CT-based brachytherapy for locally advanced cervical cancer［J］.Chin J Radiat Oncol,2014,23(5):373-376.
［21］ISOHASHI F,YOSHIOKA Y,KOIZUMI M,et al.Rectal dose and source strength of the high-dose-rate iridium-192 both affect late rectal bleeding after intracavitary radiation therapy for uterine cervical carcinoma［J］.International Journal of Radiation Oncology?Biology?Physics,2010,77(3):758-764.
［22］DIMOPOULOS JC,KIRISITS C,PETRIC P,et al.The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer:Clinical feasibility and preliminary results［J］.Int J Radiat Oncol Biol Phys,2006,66(1):83-90.

Memo

Memo:
-
Last Update: 2023-11-30